Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (61-70 of 190) with videos related to

Pageof 19
Sort By:
JCO Precision Oncology|November 22, 2021
Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic CancerRebecca S S Tidwell, Peter F Thall, Ying Yuan
Biometrics|January 13, 2021
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkersYeonhee Park, Suyu Liu, Peter F Thall, et al.
Biometrics|March 18, 2006
A geometric approach to comparing treatments for rapidly fatal diseasesPeter F Thall, Leiko H Wooten, Elizabeth J Shpall
Journal of the Royal Statistical Society. Series C, Applied Statistics|January 30, 2023
Utility-based Bayesian personalized treatment selection for advanced breast cancerJuhee Lee, Peter F Thall, Bora Lim, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 18, 2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastasesPaul Mathew, Sijin Wen, Satoshi Morita, et al.
Biometrics|March 22, 2008
Patient-specific dose finding based on bivariate outcomes and covariatesPeter F Thall, Hoang Q Nguyen, Elihu H Estey
Pharmaceutical Statistics|July 29, 2020
Comparing Bayesian early stopping boundaries for phase II clinical trialsLiyun Jiang, Fangrong Yan, Peter F Thall, et al.
Biometrics|September 17, 2002
Adaptive decision making in a lymphocyte infusion trialPeter F Thall, Lurdes Y T Inoue, Thomas G Martin
Biometrics|August 6, 2024
A generalized outcome-adaptive sequential multiple assignment randomized trial designXue Yang, Yu Cheng, Peter F Thall, et al.
British Journal of Haematology|June 13, 2002
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remissionStefan Faderl, Peter F Thall, Hagop M Kantarjian, et al.
Pageof 19

Showing results (61-70 of 190) with videos related to

Sort By:
Pageof 19
JCO Precision Oncology|November 22, 2021
Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic CancerRebecca S S Tidwell, Peter F Thall, Ying Yuan
Biometrics|January 13, 2021
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkersYeonhee Park, Suyu Liu, Peter F Thall, et al.
Biometrics|March 18, 2006
A geometric approach to comparing treatments for rapidly fatal diseasesPeter F Thall, Leiko H Wooten, Elizabeth J Shpall
Journal of the Royal Statistical Society. Series C, Applied Statistics|January 30, 2023
Utility-based Bayesian personalized treatment selection for advanced breast cancerJuhee Lee, Peter F Thall, Bora Lim, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 18, 2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastasesPaul Mathew, Sijin Wen, Satoshi Morita, et al.
Biometrics|March 22, 2008
Patient-specific dose finding based on bivariate outcomes and covariatesPeter F Thall, Hoang Q Nguyen, Elihu H Estey
Pharmaceutical Statistics|July 29, 2020
Comparing Bayesian early stopping boundaries for phase II clinical trialsLiyun Jiang, Fangrong Yan, Peter F Thall, et al.
Biometrics|September 17, 2002
Adaptive decision making in a lymphocyte infusion trialPeter F Thall, Lurdes Y T Inoue, Thomas G Martin
Biometrics|August 6, 2024
A generalized outcome-adaptive sequential multiple assignment randomized trial designXue Yang, Yu Cheng, Peter F Thall, et al.
British Journal of Haematology|June 13, 2002
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remissionStefan Faderl, Peter F Thall, Hagop M Kantarjian, et al.
Pageof 19